SCHEMBL13764004

SCHEMBL13764004

CCOC(=O)NCc1cccc(-n2nnc3cnc(Nc4ccc(C(N)=O)cc4)nc32)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 6/20 0.54
▸ GSK3B P49841 6/20 0.54
▸ AURKA O14965 4/20 0.54
▸ EIF2AK4 Q9P2K8 3/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ FLT3 P36888 3/20 0.42
▸ PTK2 Q05397 2/20 0.42
▸ EGFR P00533 1/20 0.42
▸ BLK P51451 1/20 0.42
▸ BRD4 O60885 1/20 0.42
▸ CSF1R P07333 1/20 0.41
▸ FGFR1 P11362 1/20 0.40
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ STAT6 P42226 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13303707 0.91 GSK3A (0.58) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL13764005 0.89 GSK3A (0.56) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL13764006 0.89 GSK3A (0.56) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL8297172 0.88 BRD4 (0.48) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL13764001 0.87 GSK3A (0.54) GSK3AGSK3BAURKAEIF2AK4PTK2
SCHEMBL13764007 0.87 GSK3A (0.49) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL13764002 0.86 BRD4 (0.49) GSK3AGSK3BAURKAEIF2AK4FLT3
SCHEMBL13763981 0.86 GSK3A (0.54) GSK3AGSK3BAURKAEIF2AK4NTRK1
SCHEMBL13763992 0.85 GSK3A (0.54) GSK3AGSK3BAURKAEIF2AK4NTRK1
SCHEMBL13763801 0.84 GSK3A (0.47) GSK3AGSK3BAURKAEIF2AK4PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560458-B2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-14 — — US disclosed
US-7560458-B2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-14 — — US disclosed
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors EDGARD EDDY JEAN 2009-02-05 — — US disclosed
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors EDGARD EDDY JEAN 2009-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors GSK3B, GSK3A, GYS2 GSK3A 2/4885GSK3B 1/4885AURKA 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback